- Home
- INFU vs IPHA Comparison
INFU vs IPHA Comparison
Compare INFU & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INFU
- IPHA
- Stock Information
- Founded
- INFU 2005
- IPHA 1999
- Country
- INFU United States
- IPHA France
- Employees
- INFU N/A
- IPHA N/A
- Industry
- INFU Medical/Dental Instruments
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- INFU Health Care
- IPHA Health Care
- Exchange
- INFU Nasdaq
- IPHA Nasdaq
- Market Cap
- INFU 189.2M
- IPHA 148.3M
- IPO Year
- INFU N/A
- IPHA 2019
- Fundamental
- Price
- INFU $8.07
- IPHA $1.67
- Analyst Decision
- INFU
- IPHA Strong Buy
- Analyst Count
- INFU 0
- IPHA 1
- Target Price
- INFU N/A
- IPHA $11.50
- AVG Volume (30 Days)
- INFU 66.2K
- IPHA 38.8K
- Earning Date
- INFU 03-13-2025
- IPHA 09-12-2024
- Dividend Yield
- INFU N/A
- IPHA N/A
- EPS Growth
- INFU 60.96
- IPHA N/A
- EPS
- INFU 0.07
- IPHA N/A
- Revenue
- INFU $132,783,999.00
- IPHA $36,202,722.00
- Revenue This Year
- INFU $10.23
- IPHA N/A
- Revenue Next Year
- INFU $8.80
- IPHA $101.65
- P/E Ratio
- INFU $115.14
- IPHA N/A
- Revenue Growth
- INFU 8.17
- IPHA N/A
- 52 Week Low
- INFU $5.74
- IPHA $1.29
- 52 Week High
- INFU $9.97
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- INFU 47.85
- IPHA 42.65
- Support Level
- INFU $7.86
- IPHA $1.65
- Resistance Level
- INFU $8.31
- IPHA $1.78
- Average True Range (ATR)
- INFU 0.32
- IPHA 0.10
- MACD
- INFU 0.02
- IPHA -0.02
- Stochastic Oscillator
- INFU 47.10
- IPHA 20.00
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.